Detailed explanation of the scope of application and functions of Platinib

Pralsetinib (trade name: Pujihua, English name:Pralsetinib) is a receptor tyrosine kinase RET (Rearranged during Transfection) inhibitor and is the first selective RET inhibitor approved for marketing in China. Its unique mechanism of action and remarkable efficacy have attracted much attention in cancer treatment.

Platinib is mainly used to treat many types of cancer. First, platinib showed significant therapeutic effects in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who were positive for transfection rearrangement (RET) gene fusion. By inhibiting the phosphorylation of RET and its downstream molecules, platinib can effectively inhibit the proliferation of cells expressing RET gene mutations, thereby slowing down the growth and spread of tumors.

In addition, Platinib is also indicated for adults and pediatric patients 12 years and older with advanced or metastaticRET-mutant medullary thyroid carcinoma (MTC) who require systemic treatment. For such patients, platinib can accurately target RET mutations in tumor cells, inhibit the proliferation and spread of tumor cells, and thereby improve the patient's quality of life.

Platinib has also shown good therapeutic effects in adults and pediatric patients 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer that requires systemic therapy and is refractory to radioactive iodine (if radioactive iodine is applicable) It can inhibit the proliferation and angiogenesis of tumor cells, thereby slowing down the growth and spread of tumors.

The recommended dose of platinib is400 mg, taken orally once daily on an empty stomach. Patients' health should be closely monitored while taking platinib to ensure the safety and effectiveness of the treatment. At the same time, patients should pay attention to maintaining adequate water intake, increasing the intake of fiber foods, and exercising appropriately to promote intestinal peristalsis and prevent or relieve side effects such as constipation.

In summary, platinib, as a highly selectiveRET inhibitor, provides an effective and safe treatment option for patients with RET fusion-positive non-small cell lung cancer and RET-mutant medullary thyroid cancer. By precisely targeting RET mutations in tumor cells, platinib significantly improves patients' objective response rate and disease control rate, while reducing the occurrence of side effects and improving patients' quality of life.